Qilin Zhang

Dr. Qilin Zhang

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2022 in Cell Research
Verified
Journal Article
Open access
PDF file
FZFan Zhang
Fan Zhang
QZQilin Zhang
Qilin Zhang
JZJiajun Zhu
Jiajun Zhu
BYBoyuan Yao
Boyuan Yao
CMChi Ma
Chi Ma
YZYao Zhao
Yao Zhao
Pituitary neuroendocrine tumor (PitNET) is one of the most common intracranial tumors. Due to its extensive tumor heterogeneity and the lack of high-quality tissues for biomarker discovery, the causative molecular mechanisms are far from being fully defined. Therefore, more studies are needed to improve the current clinicopathological classification system, and advanced treatment strategies such as targeted therapy and immunotherapy are yet to be explored. Here, we performed the largest integrative genomics, transcriptomics, proteomics, and phosphoproteomics analysis reported to date for a cohort of 200 PitNET patients. Genomics data indicate that GNAS copy number gain can serve as a reliable diagnostic marker for hyperproliferation of the PIT1 lineage. Proteomics-based classification of PitNETs identified 7 clusters, among which, tumors overexpressing epithelial-mesenchymal transition (EMT) markers clustered into a more invasive subgroup. Further analysis identified potential therapeutic targets, including CDK6, TWIST1, EGFR, and VEGFR2, for different clusters. Immune subtyping to explore the potential for application of immunotherapy in PitNET identified an association between alterations in the JAK1-STAT1-PDL1 axis and immune exhaustion, and between changes in the JAK3-STAT6-FOS/JUN axis and immune infiltration. These identified molecular markers and alternations in various clusters/subtypes were further confirmed in an independent cohort of 750 PitNET patients. This proteogenomic analysis across traditional histological boundaries improves our current understanding of PitNET pathophysiology and suggests novel therapeutic targets and strategies.

4 September 2023 in The Journal of Pathology: Clinical Research
Verified
Journal Article
Open access
JZJiangyan Zhao
Jiangyan Zhao
CJChenxing Ji
Chenxing Ji
HCHaixia Cheng
Haixia Cheng
ZYZhen Ye
Zhen Ye
BYBoyuan Yao
Boyuan Yao
NQNidan Qiao
Nidan Qiao
Studies describing the clinical presentation and prognosis of patients with silent PIT1 (pituitary specific transcription factor)‐lineage pituitary neuroendocrine tumors (PitNETs) are rare. We identified patients with positive PIT1 tumor staining but without evidence of hormone hypersecretion at a tertiary center. Clusters were obtained according to cell morphology and immunostaining from each patient's digitally segmented whole slide image. We compared the clinical presentations, radiological features, and prognoses of the different clusters. We identified 146 patients (68 male, 42.9 ± 14.1 years old) with silent PIT1‐lineage PitNETs. Morphology clustering suggested that tumors with large nuclei and apparent eccentricity were associated with a higher proportion of aggressiveness and a higher hazard of recurrence [hazard ratio (HR): 2.64, (95% CI, 1.06–6.55), p = 0.037]. Immunohistochemical clustering suggested that tumors with thyroid stimulating hormone (TSH) staining or all negative PIT1‐lineage hormones were associated with a higher proportion of aggressiveness and a higher risk of recurrence [HR: 12.4, (95% CI, 1.60–93.5), p = 0.015]. We obtained three‐tier risk profiles by combining morphological and immunohistochemical clustering. Patients with the high‐risk profile presented the highest recurrence rate compared with those in the medium‐risk and low‐risk profiles [HR: 3.54, (95% CI, 1.40–8.93), p = 0.002]. In conclusion, digital image analysis based on cell morphology and immunohistochemical staining allows objective stratification of patients with silent PIT1‐lineage tumors. Typical morphological characteristics of high‐risk tumors are large tumor nuclei and high eccentricity, and typical immunostaining characteristics are TSH staining or negative staining for all PIT1‐lineage hormones.

3 July 2025 in Pituitary
Verified
Journal Article
Closed access
PDF file
ZYZhen Ye
Zhen Ye
YYYifei Yu
Yifei Yu
ZCZhan Cao
Zhan Cao
ZYZhao Ye
Zhao Ye
XGXufang Gu
Xufang Gu
YZYichao Zhang
Yichao Zhang

30 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
JRJulia Rymuza
Julia Rymuza
QZQilin Zhang
Qilin Zhang
MBMateusz Bujko
Mateusz Bujko
Neuroendocrine pituitary tumors (PitNETs) are classified based on clinical manifestation and expression of pituitary cell lineage-specific transcription factors (TFs) and hormones. A subtype of acromegaly-related tumors was found to express PIT-1 and SF-1 TFs, two markers of distinct pituitary cells. They were considered as multilineage or “somatogonadotoph” tumors. The aim of our study was to determine their identity and cell type origin by extensive transcriptomic analysis. For this purpose, we analyzed the RNA sequencing (RNAseq) data from 546 PitNETs (including 193 acromegaly-related tumors) and single cell RNAseq data from somatotroph and gonadotroph tumors and normal pituitary. Somatrotroph PitNETs co-expressing PIT-1 and SF-1 TFs were found in each included RNAseq dataset. Their transcriptomic profile and activity of pituitary TFs closely resembles other somatotroph tumors, but they substantially differ from gonadotroph PitNETs yet retain activity of NR5A1 (SF-1) and expression of some of SF-1-regulated genes ( LHB and GNHRH ). SF-1 apparently regulates slightly different set of genes in double positive somatotroph PitNETs and gonadotroph tumors. Based on scRNAseq data a subcluster of normal gonadotroph cells with POU1F1 (PIT-1) expression was identified, but tumor cells of PIT-1/SF-1 PitNETs were not similar to this subtype of normal gonadotrophs. A difference in genes expression profiles between 3 subtypes of somatotroph tumors was determined by analysis of both bulk- and scRNAseq data. From transcriptomic perspective of genes-coregulation and the activity of pituitary transcription factors, acromegaly-related PitNETs co-expressing PIT-1 and SF-1 are subtype of PIT-1 lineage tumors and molecular data do not support considering them as multilineage.